Detalles de la búsqueda
1.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38755516
2.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
3.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
4.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
5.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Hematol Oncol;
42(3): e3272, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38595316
6.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
7.
Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
J Clin Exp Hematop;
64(1): 10-20, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538316
8.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
9.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol;
29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
10.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol;
29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
11.
Pooled Analysis of Pralatrexate Single-Agent Studies in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma.
Blood Adv;
2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429077
12.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
13.
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Jpn J Clin Oncol;
54(4): 376-385, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38183209
14.
Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Eur J Haematol;
112(5): 662-677, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38168033
15.
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Ann Hematol;
103(6): 2021-2031, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280061
16.
Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Int J Hematol;
119(2): 146-155, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38195971
17.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Br J Haematol;
204(3): 849-860, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37996986
18.
Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
J Clin Exp Hematop;
63(4): 219-229, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38148012
19.
An update on the developments in the treatment of adult T-cell leukemia-lymphoma: current knowledge and future perspective.
Jpn J Clin Oncol;
53(12): 1104-1111, 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592900
20.
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Int J Hematol;
118(4): 526-528, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37581752